Ocugen, Inc. examines RORα as a novel multi-pronged approach to Alzheimer

Ocugen, Inc. examines RORα as a novel multi-pronged approach to Alzheimer
Ocugen, Inc. explores RORα for Alzheimer

Ocugen, Inc. has unveiled new research exploring RORα as a potential multi-pathway target in Alzheimer disease treatment.

The study, published in Frontiers in Neuroscience, evaluates the role of RORα in several central neurological processes, including neuroinflammation, oxidative stress, mitochondrial health, and circadian regulation. The company’s scientific team aims to address the complexity of Alzheimer disease by targeting this receptor, broadening possible therapeutic strategies. $OCGN

Ocugen has previously drawn attention to the impact of geographic atrophy on retinal health in its broader research portfolio, as outlined in an earlier summary of vision and eye health findings. The company also reported raising $130 million in financing and advancing its OCU410 Phase 3 program, according to updates shared during a recent earnings call. These initiatives reflect a continued focus on both ocular and neurological disease research.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.